Clostridium difficile infection: a review of the literature  by Khan, Fahmi Yousef & Elzouki, Abdul-Naser
S6
Document heading            doi: 10.1016/S1995-7645(14)60197-8                                                     
Clostridium difficile infection: a review of the literature 
Fahmi Yousef Khan*, Abdul-Naser Elzouki
Department of Medicine, Hamad General Hospital, Hamad Medical Corporation, P.O. Box, 3050, Doha, Qatar
Asian Pac J Trop Med 2014; 7(Suppl 1): S6-S13
Asian Pacific Journal of Tropical Medicine
journal homepage:www.elsevier.com/locate/apjtm
    *Corresponding author: Fahmi Yousef Khan, (MD), Consultant, Department of 
medicine, Hamad General Hospital, P.O.Box: 3050, Doha, Qatar.
       Tel: +974 55275989
       Fax: +974 443992273
       E-mail: fakhanqal@yahoo.co.uk
1. Introduction
   Clostridium difficile (C. difficile) is a Gram-positive, 
strictly anaerobic, spore-forming bacterium that causes 
a spectrum of presentation ranging from mild, self-
limiting diarrhea, to serious diarrhea, pseudomembranous 
colitis and life-threatening fulminant colitis, which may 
result in death[1]. It was first isolated in 1935 from feces 
and meconium of asymptomatic newborn infants, and 
was originally named Bacillus difficilis because of its 
morphology, and encountered the difficulties in cultivating 
it[2]. Since then, it was believed to be a commensal organism 
until the late 1970s, when it was recognized as the etiologic 
agent of pseudomembranous colitis[3]. It is now known 
to be the cause of approximately 10%-35% of all cases 
of antibiotic-associated diarrhea and the most common 
infectious cause of nosocomial diarrhea, which is associated 
with substantial morbidity and mortality[4]; besides, it raises 
the cost for health care systems. For example, in the United 
States, the disease has an estimated annual cost of $3.2 
billion[5].
   C. difficile infection (CDI) is mainly a healthcare 
associated illness (80%), but community-acquired C. 
difficile infection (20%) is also of concern. The incidence 
of C. difficile infection is addressed well by many authors 
in the developed countries, but there is a lack of such 
information in the developing world, particularly the Gulf 
countries. The objective of this review is to describe the 
pathogenesis, changing epidemiology, risk factors and 
recent advancement in the management of CDI. 
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2. Pathogenesis 
   CDI develops when a patient ingests the spores of a 
toxigenic strain of C. difficile via personal contact or 
environment. Among healthy people, C. difficile does 
not cause problems due to in part commensal bowel 
flora and antibody-mediated immunity; however, in the 
setting of an abnormal or disrupted colonic mucosa, these 
spores colonize the bowel and subsequently germinate, 
and vegetative bacteria start producing two large toxins, 
an enterotoxin, TcdA, and a cytotoxin, TcdB, which are 
encoded by tcdA and tcdB, respectively. The two genes are 
part of the Pathogenicity Locus (PaLoc) operon, which also 
contains tcdR, tcdE and tcdC, of which tcdC is a putative 
negative regulator of tcdA and tcdB[6]. TcdA acts primarily 
on the intestinal epithelium, causing fluid secretion, 
inflammation, and tissue necrosis, whereas TcdB with 
its broad cell tropism acts as a potent cytotoxin. Some C. 
difficile strains known as NAP1/BI/027, contain an additional 
potential virulence factor (binary toxin) expressed from the 
cdtA (enzymatic component) and cdtB (binding component) 
operon. The extent to which this toxin contributes to the 
pathogenicity of C. difficile is unknown; however, C. difficile 
strain in which the binary toxin was first detected caused 
severe pseudomembranous colitis. Figure 1, describes the 
pathogenesis of CDI. 
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Figure 1. Pathogenesis of CDI.
   After binding to appropriate receptors, these toxins are 
internalized and exert their cellular effects through their 
glucosyltransferase activity by targeting and disrupting 
the intracellular signaling pathways regulated by the Rho-
family of small GTPases. Altered cellular function caused by 
TcdA and TcdB disrupts colonic mucosal integrity, activates 
colonic epithelial cell apoptosis and induces the secretion 
of a variety of pro-inflammatory cytokines[7,8]. Many of 
these effects, direct the recruitment of polymorphonuclear 
neutrophil (PMN) to the site of toxin action. PMN infiltration 
is the hallmark of a severe form of CDI known as 
pseudomembranous colitis[7]. There is no correlation between 
the severity of the disease and fecal toxin levels[9]. 
3. Epidemiology
   C. difficile is the cause of approximately 10-35% of all 
cases of antibiotic-associated diarrhea and the most 
common infectious cause of nosocomial diarrhea, which 
is associated with substantial morbidity and mortality 
rates as well as increased health care costs[4]. Data 
from Canada, Europe and the United States disclose an 
increase in the incidence and severity of the disease[10,11]. 
This has been attributed to multiple factors, including 
changing demographic situation, increased use of broad-
spectrum antibiotics and emergence of hypervirulent C. 
difficile strains known as NAP1/BI/027[12,13]. This strain is 
characterized by increased production of toxins A and B, the 
presence of an additional potential virulence factor (binary 
toxin) and resistance to newer fluoroquinolone antibiotics, 
such as moxifloxacin[14]. Since the late 1990s until 2007, this 
strain was not reported outside Europe and North America, 
but a survey of the period 2008-2010 showed global spread 
had occurred[15]. This can be explained by the movement 
of people, animals, vectors, and inanimate objects across 
international borders[13]. The incidence of CDI varies widely 
in different studies depending on the type of hospital 
care (acute care vs. long term), patient population (elderly 
vs. young) and the presence or absence of nosocomial 
outbreaks. For example, the incidence of CDI is increased 
in long term hospitals due to prolonged hospitalization and 
increased number of elderly patients (patients older than 65 
years). Moreover, high incidence of CDI has been reported 
during outbreaks in many countries such as Canada, Europe 
and the USA. Generally, the overall incidence of CDI ranges 
from 2 to 6 cases per 10 000 patient days[16-19], and there is no 
sexual predilection. Increased incidence of CDI is coupled 
with more serious clinical presentation and, increased 
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morbidity and mortality. The 30-d mortality ranges from 
24.0% to 50.0%[20,21].
4. Risk factors
   The chief risk factor for the disease is prior to expose 
antimicrobials. In the hospital setting, the majority of CDI 
cases is associated with the use of antibiotics. However, up 
to 2/3 of cases of community-acquired CDI in a recent study 
did not have antibiotics in the 90 d prior to the development 
of symptoms suggesting a different pattern of disease 
between community-acquired and nosocomial cases[9]. 
   Nearly all antimicrobials have been reported to be 
associated with CDI. Agents who are active against anaerobic 
bacteria are considered to present the greatest risk factor, 
presumably because of their ability to alter intestinal 
microecology[22]. The risk of developing disease after 
exposure to antimicrobials is highly variable and depends 
on host factors (age, diet, immune system function, etc.), the 
type and dose of antibiotic, and the duration of treatment. 
Although clindamycin usage was closely linked with the 
disease historically and still constitutes to be a major risk 
factor, more cases at the present are attributed to therapy 
with β-lactam agents because of their common use[23]. Other 
risk factors include advanced age (>65 years), recent surgery 
(transplant, gastrointestinal procedures), proton pump 
inhibitors, immunosuppressant, underlying debilitating 
conditions, inflammatory bowel disease, prolonged 
hospitalisation (>15 d), and nasogastric tube feeding[24,25].  
5. Clinical features
   Asymptomatic carriers vary from 2% in the community 
to 20%-30% or more in hospitalized adults[26]. Although 
asymptomatic, these individuals serve as a reservoir for 
environmental contamination[27]. The incubation period 
between spore ingestion and the onset of the disease has not 
been determined. However, most patients develop diarrhea 
during or shortly after taking antibiotics, or up to 8-10 weeks 
after its discontinuation[27-29]. CDI has a wide spectrum range 
of clinical presentations from mild, self-limiting diarrhea, 
to serious diarrhea, pseudomembranous colitis and life-
threatening fulminant colitis, which may result in death. 
Watery diarrhea is the cardinal symptom of CDI[28]; it varies 
from mild, moderate to severe. Patients with colitis (with or 
without pseudomembranous colitis) usually present with 
watery diarrhea up to 10-15 times daily, abdominal cramping 
and pain, fever, anorexia and nausea[30]. A leukemoid 
reaction, hypoalbuminemia and occult colonic bleeding 
may occur, but visible blood is rare. Approximately, 3% to 
8% of CDI patients develop a fulminant disease, defined as 
patients whose course is complicated by perforation, severe 
ileus with toxic megacolon, hypotension requiring pressors, 
or refractory septicemia[31,32]. Although diarrhea may be 
present, these patients may have little or no diarrhea as a 
result of toxic megacolon and paralytic ileus.
6. Diagnosis
   The diagnosis of CDI is based on the clinical features, 
confirmation of the presence of either toxin A alone 
or toxins A and B together in the stool, and sometimes 
endoscopy to verify pseudomembranous colitis. CDI should 
be suspected in any hospitalized patient who develops 
diarrhea or any person in the community who develops 
diarrhea after a course of antibiotics or in association with 
immunosuppressive therapy. However, diagnostic tests 
to confirm CDI are essential. Testing for C. difficile or its 
toxins should be performed only on diarrheal (unformed) 
stool unless ileus due to C. difficile is suspected. Table 2 
summarizes the accuracy of various diagnostic tools used for 
the diagnosis of CDI. 
   The tissue culture cytotoxicity assay which detects the 
presence of C. difficile cytotoxin (toxin B) in stool filtrate 
is considered to be the “gold standard” for diagnosis as it 
can detect as little as 10 pg of toxin in stool and have a high 
sensitivity (94%-100%) and specificity (99%-100%) shown in 
Table 2. However, the test has long turn-around time (1-3 d) 
and high cost and it requires a tissue culture facility[33-35].
   Enzyme immunoassay (EIA) for C. difficile glutamate 
dehydrogenase (GDH) antigen is used to detect the presence 
of the enzyme GDH, which is produced by all strains of C. 
difficile isolates, with toxigenic and non-toxigenic. This 
test is highly sensitive (75%-90%), and has a high negative 
predictive value (95%-100%). However, it is no more than 50% 
specific with low positive predictive value, because it does 
not differentiate toxin-producing from non-toxigenic strains 
of C. difficile. Moreover, antibodies against C. difficile GDH 
in this test may cross-react with the same enzyme in other 
clostridial species[35,36]. To overcome this problem and to 
increase the specificity of the test, a 2-step method has 
been recently suggested by the Infectious Diseases Society 
of America/Society for Healthcare of America guidelines 
on diagnostic testing of C. difficile. This strategy uses EIA 
detection of GDH and then uses the cell cytotoxicity assay 
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or toxigenic culture as the confirmatory test for glutamate 
dehydrogenase-positive stool specimens only[37].
Table 2
Sensitivity and specificity of test used for the diagnosis of CDI. %.
Laboratory test Sensitivity Specificity
Tissue culture cytotoxicity assay 94-100 99-100
Glutamate dehydrogenase enzyme immunoassay 75-90 <50
Enzyme immunoassay for C. difficile toxin 65-85 95-100
RT-PCR 88-100 96-100
Anaerobic culture of stool 89-100 48-68
   EIA for C. difficile toxin is used to detect the presence 
of C. difficile toxins A and B in stool. It remains the main 
diagnostic modality in most clinical settings, because of its 
rapidity and ease of performance. This test provides results 
within 2 to 6 h with a specificity of 95%-100%; however, it has 
reduced sensitivity (65%-85%)[33-38]. A relatively high false-
negative rate, could be explained by the fact that 100 to 1 000 
pg of a toxin must be present for the test to be positive[3].
   Diagnostic strategies targeting nucleic acids, including 
PCR methods and RT-PCR methods have been developed 
for the detection of the genes encoding TcdA and/or 
TcdB[39]. Infectious Diseases Society of America/Society for 
Healthcare of America guidelines on diagnostic testing of C. 
difficile suggest that more data are needed on nucleic acid 
amplification tests before it can be implemented for wide-
scale use[37]. However, RT-PCR methods for the detection of 
C. difficile toxin B gene have recently been employed with 
high sensitivity (88%-100%) and specificity (96%-100%)[40-42].  
   C. difficile can be isolated by means of anaerobic culture 
of stool. Although the test is highly sensitive, it is seldom 
used for clinical diagnosis, as it takes 2-3 d to complete and 
does not distinguish toxigenic strains from non-toxigenic 
strains[43]. However, this test is essential for epidemiological 
studies (i.e., for strain typing in outbreaks of nosocomial 
infection)[37].
   Sigmoidoscopy and colonoscopy are not indicated for 
patients with classic clinical findings and a positive stool 
toxin assay and should be avoided in fulminant colitis 
because of the risk of perforation[44,45]. However, endoscopy 
is helpful in special situations such as when other diseases 
need to be ruled out, the diagnosis is in doubt or the clinical 
situation demands rapid diagnosis, or a stool sample cannot 
be obtained because ileus develops[44-48].
   Radiographic imaging studies can be used to assist the 
severity of CDI. Abdominal imaging studies may reveal dilated 
colon, air-fluid levels (mimicking an intestinal obstruction 
or ischemia), and “thumb printing” (scalloping of the bowel 
wall) due to an edematous colonic mucosa[43]. Abdominal 
CT scanning also can help categorize the severity of colitis, 
and it can diagnose fulminant colitis rapidly. It may show 
ascites, free air, colon wall thickening, or dilation[25,49]. 
7. Treatment 
   The first step in treating a patient with documented or 
suspected CDI includes stopping the inciting agent such 
as antimicrobials, if possible, and providing appropriate 
supportive care with hydration and electrolyte replacement 
Table 1
Treatment of CDI.
Clinical picture Treatment 
Non-severe CDI
Metronidazole: 250 mg orally 4 times daily or 500 mg orally every eight hours daily) given for 10 d; If failed to response to 
metronidazole after 5-7 d or patient has contraindications.
Vancomycin: 125-250 mg orally 4 times daily for 10 d
Alternative therapy: Fidaxomicin 200 mg orally twice daily for 10 d; Fusidic acid 500 mg orally 3 times daily for 10 d; 
Teicoplanin 400 mg orally twice daily for 10 d; Bacitracin 20 000 IU orally 4 times daily for 10 d; Nitazoxanide 500 mg orally 
twice daily for 10 d.
Fulminant disease  (severe CDI) 
(Perforation, severe ileus with toxic 
megacolon, hypotension requiring 
pressors, or refractory septicemia) 
Vancomycin (125 mg p.o. or via nasogastric tube/every 6 h daily for 10 d) plus intravenous metronidazole (500 mg every 
8 h daily for 10 d); if severe paralytic ileus or toxic colon is suspected, treat rectal vancomycin 500 mg in 250 mL normal 
saline every 6 h daily as a retention enema; If medical therapy fails or perforation develop, patients will be in surgical 
intervention with colectomy and ileostomy.
Recurrence of CDI 
(Reappearance of diarrhea and 
other symptoms after successful 
treatment)
First recurrence: It can be treated with the same drug as was used during the first episode.
Second or subsequent recurrence: 
High dose vancomycin: 250-500 mg orally every 6 h for 10 d followed by tapered doses of vancomycin for 21 d or by pulsed-dosing 
of vancomycin therapy 125 mg every 3 d for 21 d
Long, tapered vancomycin over six weeks: 1st week: 125 mg 4 times daily; 2nd week: 125 mg 2 times daily; 3rd week: 125 mg once 
daily; 4th week: 125 mg every other day; 5th and 6th week: 125 mg every third day.
Administration of donor stool
Vancomycin with rifampin vancomycin: 125 mg orally 4 times per day and oral rifampin 600 mg 2 times per day for 7-10 d
Vancomycin with colestipol
Vancomycin with the probiotic Saccharomyces boulardii 
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as needed[37]. Anti-diarrheal medications should be avoided 
as they may obscure symptoms and precipitate toxic 
megacolon. 
   Metronidazole and vancomycin are the mainstays of 
antimicrobial therapy for CDI. Although both drugs are 
effective for treatment of this disease, they are matters of 
much ongoing debate, as none of them is clearly superior 
to the initial cure of this infection[26,50,51]. Therefore, local 
guidelines, which are based on local epidemiology of CDI, 
should be developed in each country to solve this debate, 
as the majority of treatment guidelines are formulated in 
the developed countries. Treatment modalities of CDI are 
summarized in Table 1. 
8. Metronidazole
   The preference of metronidazole as a first-line treatment 
is supported by its low-cost and avoidance of selection for 
vancomycin-resistant enterococci, even though subsequent 
data have suggested that the risk of bowel, vancomycin-
resistant enterococci colonization is equivalent with 
these two drugs[52]. Metronidazole also has the advantage 
of allowing intravenous administration in patients who 
are unable to take oral medications. Oral or intravenous 
metronidazole therapy (250 mg four times daily or 500 mg 
every 8 h daily) given for 10 d is recommended as the initial 
treatment of choice.
9. Vancomycin
   Vancomycin can be used as initial therapy for patients 
with contraindications or intolerance to metronidazole or for 
those who have severe CDI or who are living in areas with 
local prevalence of the NAP1/027[53]. Moreover, vancomycin 
should be reserved for patients who fail to respond to 
metronidazole after 5-7 d. Vancomycin (125-250 mg orally 
four times daily for 10 d) is the recommended second line 
therapy.
   In the recommended doses, metronidazole and vancomycin 
have similar efficacy, with response rates 90%-97%. The 
therapeutic response usually involves the resolution of fever 
and of diarrhea on the fourth or fifth day. 
   Patients with fulminant disease should be treated with 
both oral vancomycin and intravenous metronidazole despite 
a lack of evidence from clinical trials about combination 
therapy. When severe paralytic ileus is suspected, 
intraluminal vancomycin via a long catheter in the small 
intestine or retention enema should be considered[49]. 
   In patients with suspected CDI who received empiric 
antimicrobial therapy, if the stool toxin assay result is 
negative, the decision to stop, or to continue treatment 
must be individualized[49]. 
   Other antibiotics that may be considered as alternative 
therapy for CDI in the unusual events (e.g. allergy or 
intolerance to both first-line agents) include fidaxomicin, 
bacitracin, teicoplanin, fusidic acid and nitazoxanide, 
rifaximin and rifampin. Most of the active comparator 
studies found no statistically significant difference in 
efficacy between vancomycin and these agents for initial 
therapy of CDI except teicoplanin and fidaxomicin. 
Teicoplanin appears to be better than vancomycin 
for bacteriologic cure and has borderline superior 
effectiveness in terms of symptomatic cure[54], while 
fidaxomicin appears superior to vancomycin in terms of 
lower recurrence rates and global clinical cure rates (i.e., 
clinical cure rates combined with recurrence rates)[10].
   None antimicrobial therapies such as intravenous 
immunoglobulin, specific monoclonal antibodies therapy, 
toxin-binding agents (e.g., cholestyramine, tolevamer), 
probiotics [e.g., Saccharomyces boulardii (S. boulardii)] and 
faecal therapy have been studied for use as stand-alone 
treatments or in combination with standard therapy for CDI. 
   Surgical intervention (colectomy) is indicated in patients 
with toxic megacolon who are not responding to medical 
treatment, in patients with ongoing severe sepsis despite 
antibiotic treatment, and/or when colonic perforation is 
clinically suspected[55].
   After effective treatment of CDI, about 10%-30% of 
patients with CDI experienced recurrence[56]. These 
recurrences can correspond to either a relapse of the 
original infection or a reinfection with a different strain. 
Risk factors for recurrent CDI include advanced age, 
administration of additional antibiotics, prolonged hospital 
stay, concomitant use of antacid medications, and long-
term dialysis[57,58]. First recurrences can be treated using 
the same drug as was used during their first episode[49]. For 
patients with multiple recurrences of CDI or with CDI that 
is not responsive to standard treatments, there is a lack of 
randomized, large prospective, controlled clinical trials to 
suggest the optimal approach to these patients. However, 
higher doses of orally administered vancomycin (250-
500 mg every 6 h for 10 d) followed by tapered or pulsed 
doses of vancomycin have been used[49,59,60]. In addition, 
a tapered regimen of vancomycin consisted of 500 mg/d 
during Week 1, 250 mg/d during Week 2, 125 mg/d during 
Week 3, and a pulsed dose of 125 mg every 3 d during 
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Weeks 4-6 has been found to be effective[61]. Failure of 
these treatment strategies may prompt administration of 
donor stool from a healthy individual[62]. This treatment 
modality is called fecal microbiota transplant. The 
infusion of a fecal suspension from a healthy individual 
into the gastrointestinal tract of a patient with CDI can be 
achieved by colonoscopy, retention enema, nasogastric/
nasoduodenal tube, self-administered enema or by 
esophagogastroduodenoscopy[62-65]. In 317 patients with 
recurrent CDI and pseudomembranous colitis treated across 
27 case series and reports, fecal microbiota transplant 
was highly effective, showing disease resolution in 92% 
of cases[66]. Other therapeutic options include treatment 
with vancomycin in combination with rifampin or with 
anion-binding resins such as colestipol[67,68], or treatment 
with vancomycin followed by course of rifaximin[69]. Small 
randomized clinical trials support the use of vancomycin 
with the probiotic S. boulardii[70-73]. A meta-analysis of 
six RCTs of different probiotics, including S. boulardii 
showed that probiotics had a significant efficacy to prevent 
subsequent recurrences of CDI[74]. Therapeutic options of 
recurrent CDI are summarized in Table 1.
10. Prevention 
   Prevention of CDI is challenging health authorities. 
However, preventive measures are taken such as 
implementation of infection-control measures (contact 
i so la t ion  and fo l lowing  good  hand-washing  by 
everyone). In addition, the cornerstone to controlling 
this infection is the control of antimicrobial prescribing. 
A multidisciplinary antibiotic management program to 
restrict the inappropriate use of antibiotics can lead to a 
significant decrease in nosocomial infections caused by C. 
difficile[25].
   In conclusion, CDI is the cause of approximately 10%-
35% of all cases of antibiotic-associated diarrhea and the 
most common infectious cause of nosocomial diarrhea, 
which is associated with substantial morbidity, mortality 
and increased healthcare costs. Spectrum of presentation 
of CDI ranges from mild, self-limiting diarrhea, to 
serious diarrhea, pseudomembranous colitis and life-
threatening fulminant colitis, which may result in death. 
Prompt identification of patients with symptomatic CDI 
is essential as majority of patients respond quickly to 
antimicrobial therapy. Prevention is best accomplished 
by implementation of infection-control measures and by 
judicious use of antimicrobial agents.
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